IGFBP-7 has been evidenced as a serum biomarker for diastolic dysfunction associated with vascular remodelling and cardiac hypertrophy and fibrosis, in the metabolic syndrome [145]. The gene discussed is IGFBP7; the disease is cardiac hypertrophy.